After the recommendations by the US FDA, the UAE Ministry of Health and Prevention (MoHAP) has recently suspended the registration, importation, and distribution of all drugs containing ranitidine. The step has been undertaken as a precautionary measure against possible contamination of the drug with a potentially carcinogenic impurity, known as N-nitrosodimethylamine (NDMA). The decision was based on the recommendations by the US FDA, the EMA and the Health Canada following the reports on the possible contamination of the tablet with NDMA.
Furthermore, the Health Ministries from other GCC countries have also passed similar circulars on the suspension of all drugs containing ranitidine. However, the Ministry has urged the patients to continue with their existing prescriptions unless an alternative is prescribed to them. Source: Gulf News, Khaleej Times Which of the following anti-reflux…
